Skip to main content

Cerliponase alfa Side Effects

Medically reviewed by Last updated on Jul 14, 2023.

Applies to cerliponase alfa: intracerebroventricular solution.

Serious side effects of Cerliponase alfa

Along with its needed effects, cerliponase alfa may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking cerliponase alfa:

More common

Incidence not known

Other side effects of Cerliponase alfa

Some side effects of cerliponase alfa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to cerliponase alfa: injectable kit.


The most frequently reported side effects were pyrexia, ECG abnormalities, decreased cerebrospinal fluid (CSF) protein, vomiting, seizures, hypersensitivity, increased CSF protein, hematoma, headache, irritability, pleocytosis, device-related infection, bradycardia, feeling jittery, and hypotension.[Ref]


Hypersensitivity reactions occurred in 14 of 24 patients with severe hypersensitivity reactions occurring in 3 patients. No patients discontinued therapy due to hypersensitivity. The most common manifestations included pyrexia with vomiting, pleocytosis, or irritability, which are inconsistent with classic immune mediated hypersensitivity. These reactions were observed during or within 24 hours after the infusion and did not interfere with treatment. Symptoms resolved over time or with administration of antipyretics, antihistamines and/or glucocorticosteroids.

Very common (10% or more): Hypersensitivity reactions (58%)

Nervous system

Seizures occurred in 12 of 24 patients; seizure types included atonic, generalized tonic-clonic, focal, and absence seizure. Seizures were managed per standard of care and did not result in treatment discontinuation.[Ref]

Very common (10% or more): Seizure (50%), headache (17%), pleocytosis (17%)

Postmarketing reports: Meningitis[Ref]


Very common (10% or more): ECG abnormalities (71%), hematoma (21%)

Common (1% to 10%): Bradycardia, hypotension[Ref]

ECG abnormalities included non-specific repolarization abnormality, notched QRS, ST segment elevation, biphasic T wave abnormality, supraventricular asystole, bradycardia, sinus tachycardia, and intraventricular conduction delay.

Hematoma reactions presented as hematoma, post-procedural hematoma, traumatic hematoma, and subdural hematoma, none of which required treatment and did not interfere with infusion.

Hypotension was reported in 2 patients; these patients did not require treatment alterations as reactions resolved spontaneously or after IV fluids.[Ref]


Very common (10% or more): Device-related complication (50%)

Common (1% to 10%): Device-related infection[Ref]

Device-related adverse reactions occurred in 50% of symptomatic pediatric patients during clinical studies and included infection (e.g., Propionibacterium acnes, Staphylococcus epidermidis), deliver system-related complications, and pleocytosis. Complications of the non-implanted delivery system components occurred in 9 of these patients (38%). Four patients (16%) had device-related adverse reactions that required medical intervention including 2 patients (8%) with intraventricular access device-related central nervous system infections and 1 patient (4%) each with leakage of the intraventricular access device and pleocytosis.[Ref]


Very common (10% or more): Vomiting (63%)[Ref]


Very common (10% or more): Pyrexia (71%), CSF protein decreased (71%), CSF protein increased (21%)

Common (1% to 10%): Feeling jittery[Ref]


Antidrug antibodies (ADAs) were detected in both serum and CSF in 79% and 33%, respectively, of patients treated with this drug for up to 161 weeks. Patients who experienced hypersensitivity reactions were tested for drug-specific IgE and were found to be negative, including 3 patients who reported grade 3 (severe) hypersensitivity reactions. No association has been found between serum CSF ADA titers and incidence/severity of hypersensitivity.[Ref]

Very common (10% or more): Antidrug antibodies developed (up to 79%), hypersensitivity (46%)[Ref]


Very common (10% or more): Irritability (17%)[Ref]


Frequency not reported: Hypoxia[Ref]

Frequently asked questions


1. EMEA. European Medicines Agency. EPARs. European Union Public Assessment Reports. 2007.

2. Product Information. Brineura (cerliponase alfa). BioMarin Pharmaceutical Inc. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.